Author

F. Acconcia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1

Frequent Co-Authors

C. Busonero· 3 shared S. Leone· 3 shared F. Bianchi· 2 shared M. Cipolletti· 2 shared S. Bartoloni· 2 shared C. Klemm· 1 shared S. Pescatori· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Busonero

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer

S. Bartoloni, S. Pescatori, F. Bianchi, M. Cipolletti, F. Acconcia

This study identifies ALK and MELK inhibition as potential targets for specific breast cancer subtypes by showing their impact on ER stability and proliferation.

bioRxiv · Dec 19, 2023Cancer Biology

Real-time measurement of E2:ERα transcriptional activity in living cells.

M. Cipolletti, S. Leone, S. Bartoloni, C. Busonero, F. Acconcia

This study develops stable cell lines to monitor real-time ERα transcriptional activity in response to E2 and identifies biphasic dynamics and dose-dependent effects.

bioRxiv · Jan 11, 2020Physiology

In silico screening for ERα downmodulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells

C. Busonero, S. Leone, F. Bianchi, F. Acconcia

The paper identifies thioridazine as an anti-proliferative agent effective against ERα-expressing breast cancer cells resistant to tamoxifen.

bioRxiv · May 18, 2018Cancer Biology

A Functional Drug Re-Purposing Screening Identifies Carfilzomib As A Drug Preventing 17β-Estradiol: ERα Signaling And Cell Proliferation In Breast Cancer Cells

C. Busonero, S. Leone, C. Klemm, F. Acconcia

This study identifies carfilzomib as a drug that prevents 17β-estradiol:ERα signaling and inhibits cell proliferation in breast cancer cells, showing efficacy in tamoxifen-resistant models.

bioRxiv · May 3, 2017Cancer Biology